Ken Maes
Overview
Explore the profile of Ken Maes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
1039
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fan R, Satilmis H, Vandewalle N, Verheye E, de Bruyne E, Menu E, et al.
Blood Cancer J
. 2023 Dec;
13(1):188.
PMID: 38110349
Acute Myeloid Leukemia (AML) is a heterogeneous disease with limited treatment options and a high demand for novel targeted therapies. Since myeloid-related protein S100A9 is abundantly expressed in AML, we...
2.
Emde-Rajaratnam M, Beck S, Benes V, Salwender H, Bertsch U, Scheid C, et al.
Front Immunol
. 2023 Nov;
14:1286700.
PMID: 38035078
Background: Immunotherapeutic targets in multiple myeloma (MM) have variable expression height and are partly expressed in subfractions of patients only. With increasing numbers of available compounds, strategies for appropriate choice...
3.
Ryckx S, De Schepper J, Giron P, Maes K, Vaeyens F, Wilgenhof K, et al.
J Med Case Rep
. 2023 May;
17(1):195.
PMID: 37179382
Introduction: Pure androgen-secreting adrenocortical tumors are a rare but important cause of peripheral precocious puberty. Case Presentation: Here, we report a pure androgen-secreting adrenocortical tumor in a 2.5-year-old boy presenting...
4.
Fan R, Satilmis H, Vandewalle N, Verheye E, Vlummens P, Maes A, et al.
J Immunother Cancer
. 2023 Jan;
11(1).
PMID: 36650020
Background: Immunotherapy emerged as a promising treatment option for multiple myeloma (MM) patients. However, therapeutic efficacy can be hampered by the presence of an immunosuppressive bone marrow microenvironment including myeloid...
5.
De Becker A, Heestermans R, De Brouwer W, Bockstaele K, Maes K, Van Riet I
Front Bioeng Biotechnol
. 2022 Nov;
10:1008271.
PMID: 36324892
Mesenchymal stromal cells (MSCs) are non-hematopoietic cells that have a broad therapeutic potential. To obtain sufficient cells for clinical application, they must be expanded . In the initial expansion protocols...
6.
Fan R, De Beule N, Maes A, de Bruyne E, Menu E, Vanderkerken K, et al.
Front Immunol
. 2022 Oct;
13:1016059.
PMID: 36304465
The success of immunotherapeutic approaches in hematological cancers is partially hampered by the presence of an immunosuppressive microenvironment. Myeloid-derived suppressor cells (MDSC) are key components of this suppressive environment and...
7.
Heestermans R, De Brouwer W, Maes K, Vande Broek I, Vaeyens F, Olsen C, et al.
Cancers (Basel)
. 2022 Oct;
14(19).
PMID: 36230824
The analysis of bone marrow (BM) samples in multiple myeloma (MM) patients can lead to the underestimation of the genetic heterogeneity within the tumor. Blood-derived liquid biopsies may provide a...
8.
Vlummens P, Verhulst S, de Veirman K, Maes A, Menu E, Moreaux J, et al.
Front Cell Dev Biol
. 2022 Jun;
10:879057.
PMID: 35757005
Multiple myeloma (MM) is an incurable clonal plasma cell malignancy. Subsets of patients have high-risk features linked with dismal outcome. Therefore, the need for effective therapeutic options remains high. Here,...
9.
De Beck L, Awad R, Basso V, Casares N, De Ridder K, De Vlaeminck Y, et al.
Front Immunol
. 2022 May;
13:799636.
PMID: 35634329
Immunotherapy has improved the treatment of malignant skin cancer of the melanoma type, yet overall clinical response rates remain low. Combination therapies could be key to meet this cogent medical...
10.
De Smedt E, Devin J, Muylaert C, Robert N, Requirand G, Vlummens P, et al.
Blood Adv
. 2021 May;
5(9):2325-2338.
PMID: 33938943
Multiple myeloma (MM) is an (epi)genetic highly heterogeneous plasma cell malignancy that remains mostly incurable. Deregulated expression and/or genetic defects in epigenetic-modifying enzymes contribute to high-risk disease and MM progression....